April 27, 2018Otsuka Pharmaceutical Factory acquires all the shares ofLilium Otsuka held by Otsuka Medical Devices,making it a whollyowned subsidiary
Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President andRepresentative Director: Shinichi Ogasawara; “OPF”) has signed a Share Purchase Agreement toacquire all the shares of Lilium Otsuka Co., Ltd. (Head Office: Sagamihara, Kanagawa, Japan; President
and Representative Director: Isao Shirasaki; “Lilium Otsuka”) held by Otsuka Medical Devices Co., Ltd.
(Head Office: Chiyoda-ku, Tokyo, Japan; President and Representative Director: Noriko Tojo; “Otsuka
Medical Devices”). The acquisition of the shares has been completed today and Lilium Otsuka becomesa wholly owned subsidiary of OPF.
Lilium Otsuka has engaged in the business as one of the wholly owned subsidiaries of Otsuka MedicalDevices which oversees medical device operations of the Otsuka Group. In April 2016, OPF and Lilium
Otsuka signed an exclusive sales agreement for the portable ultrasonic diagnostic device “Lilium® α-200”(“Lilium α-200”). OPF has been expanding sales of the product by utilizing its wide range of network
through clinical nutrition products in settings from acute care hospitals to homes. By making Lilium
Otsuka a wholly owned subsidiary of OPF and integrating manufacturing and distribution, OPF willfurther strengthen the business structure and strategically develop products related to nephrology, renal
surgery, and urology of the Otsuka Group. We can establish a system which can smoothly meet requests
from patients and healthcare professionals by this agreement.
Based on the corporate philosophy of “Otsuka-people creating new products for better healthworldwide,” the Otsuka Group is dedicated to contributing to the health of people around the world.
About Lilium α-200
Lilium α-200 was developed by Lilium Otsuka and launched in November 2015. The product is a
medical device which can visually indicate the amount of urine in the bladder noninvasively using
ultrasonic technology (medical device approval No: 227ADBZX00146000). It can comprehensively
evaluate bladder function by urine volume monitor (post-void residual measurement or 24-hour periodicmeasurement) and is useful for the care after removal of indwelling urethraｌ catheters and removing
diaper at an appropriate time. It is expected to become an effective tool for patients to support urinary
independence and promote recovery at home.

-1-Company Profile
Otsuka Pharmaceutical Factory, Inc.
Established:

October 7, 1969 (founded September 1, 1921)

Capital:

80 million yen

Representative:

Shinichi Ogasawara, President and Representative Director

Head Office:

115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima 772-8601, Japan

Number of Employees:

Business Description:

Website (URL):

2,297 (as of December 31, 2017)
Manufacture, sale, import and export of clinical nutrition products, and otherpharmaceutical products, medical devices, and functional foods, etc.
http://www.otsukakj.jp/en/

Otsuka Medical Devices Co., Ltd.
Established:February 15, 2011

Capital:7.55 billion yen

Representative:

Noriko Tojo, President and Representative Director

Head Office:

2-9 Kanda Tsukasamachi, Chiyoda-ku, Tokyo 101-0048, Japan

Number of Employees:

Business Description:

Website (URL):15 (as of December 31, 2017)
Overseeing medical device operations within the Otsuka Group and thebusiness activities of companies engaged in related businesses, as well as all
operations incidental to the foregoing activities
http://www.omd.otsuka.com/en/

Established:

January 29, 2015

Capital:

75 million yen

Representative:

Isao Shirasaki, President and Representative Director

Head Office:

4-12-6, Chiyoda, Chuo-ku, Sagamihara, Kanagawa 252-0237, Japan

Number of Employees:

Lilium Otsuka Co., Ltd.

Business Description
Website (URL)

18 (as of December 31, 2017): Research and development, manufacturing and marketing of medical devices
and related products: http://www.lilium.otsuka/en/-2-